

Polymorphism in the Binary System of Enantiomeric Dihydropyridines

Judith M. Rollinger and Artur Burger

Institute of Pharmacy / Pharmacognosy, University of Innsbruck, Josef-Moeller-Haus, Innrain 52, A-6020 Innsbruck, Austria; e-mail: judith.rollinger@uibk.ac.at

Dihydropyridine channel blockers are widely used in the treatment of hypertension and angina pectoris. They are predominantly chiral molecules and commercially used as racemates. Furthermore, polymorphism is a very common phenomenon among this group of drug substances and may additionally complicate the analytic and standardization of these compounds.

The aim of this study was to characterize and identify the crystal forms of enantiomers, and racemic mixtures of three chiral dihydropyridines, namely nitrendipine [1], arnlodipine besylate, and felodipine [2, 3]. They were investigated by thermoanalytical, spectroscopical and X-ray diffraction methods. The binary melting phase diagrams of nitrendipine and felodipine were established by DSC and hot stage microscopy, allowing determination of the racemic species and an understanding of the complex thermal behavior.

Three monotropically related modifications of racemic nitrendipine were characterized and identified as a racemic compound (mod. I, mp. $\sim 158^{\circ}\text{C}$) and two conglomerates (mod. II, mp. $\sim 134^{\circ}\text{C}$, and mod. III, mp. $\sim 126^{\circ}\text{C}$). In the racemic mixture, arnlodipine besylate crystallizes as anhydrate (mod. I, mp. $\sim 198^{\circ}\text{C}$) and stable monohydrate. Dimorphism was found in the case of felodipine enantiomers (En-mod. I, mp. $\sim 144^{\circ}\text{C}$; En-mod. II, mp. $\sim 133^{\circ}\text{C}$), as well as in the racemic mixture (mod. I, mp. $\sim 145^{\circ}\text{C}$; mod. II, mp. $\sim 135^{\circ}\text{C}$). An unusual continuous series of solid solutions is manifested between their higher melting crystal forms which defines felodipine mod. I as pseudoracemate.

- [1] A. Burger, J. M. Rollinger and P. Brüggegger, *J. Pharm. Sci.* 86, 674-679 (1997).
- [2] S. Srèiè, J. Kerè, U. Urleb, I. Zupanèiè, G. Lahajnar, B. Kofler and J. Šmid-Kobar, *Int. J. Pharm.* 87, 1-10 (1992).
- [3] J. M. Rollinger, M. Kuhnert-Brandstätter and A. Burger, *Sci. Pharm.* 67, S 94 (1999).